Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.27Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.Company Guidance
During the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call, the company provided guidance on advancing their lead candidate, zervimesine (CT1812), into registrational trials for Alzheimer's disease and dementia with Lewy bodies (DLB). The company plans to submit final study documents to the FDA and request end of Phase II meetings for both indications. Their strategic decision to conclude the Phase II dry AMD study was made to focus resources on Alzheimer's and DLB programs, extending their cash runway into Q4 2025. Cognition reported a net loss of $34 million for 2024 and utilized an ATM facility to raise $12.8 million. They hold approximately $25 million in cash and $50 million in obligated grant funds. The company is also working on securing non-dilutive funding and is confident in regaining NASDAQ compliance within the allotted grace period.Strong Efficacy Signals for Zervimesine
The company reported strong efficacy signals from two studies involving Alzheimer's disease and dementia with Lewy bodies (DLB), indicating potential value for patients and investors.
Cash Runway Extension
The strategic decision to conclude the Phase II dry AMD study is projected to result in cost savings that extend the company's cash runway into the fourth quarter of 2025.
Provisional Patent Applications Filed
Cognition Therapeutics has filed provisional patent applications for a novel chemical process developed for the manufacture of zervimesine, supporting future clinical studies and potential commercial manufacturing.
Progress in Manufacturing Capabilities
The company is working with a domestic contract manufacturing organization capable of producing commercial quantities of zervimesine, positioning them for potential future market demands.
---
CGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $0.45 | $0.43 | -4.44% |
| Nov 13, 2024 | $0.60 | $0.54 | -10.00% |
| Aug 08, 2024 | $0.58 | $0.58 | 0.00% |
| May 07, 2024 | $1.99 | $1.92 | -3.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cognition Therapeutics (CGTX) report earnings?
Cognition Therapeutics (CGTX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cognition Therapeutics (CGTX) earnings time?
Cognition Therapeutics (CGTX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CGTX EPS forecast?
CGTX EPS forecast for the fiscal quarter 2025 (Q1) is -0.12.
---